LO-015 Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in a phase 2 trial in systemic lupus erythematosus (SLE): achievement of sustained SRI(4), BICLA, and dual responses over 48 weeks
Richard Furie(Hofstra University), Eric F. Morand(Novartis (Switzerland)), Cristina Arriens(Oklahoma Medical Research Foundation), Coburn Hobar(Bristol-Myers Squibb (United States)), Shalabh Singhal(Integrated BioTherapeutics (United States)), Ayanbola Elegbe(Bristol-Myers Squibb (United States)), Subhashis Banerjee(Bristol-Myers Squibb (United States)), Kenneth B Kalunian(University of California San Diego), Marilyn C. Pike(Bethesda Hospital), Ronald van Vollenhoven(Amsterdam University Medical Centers), Samantha Pomponi(Bristol-Myers Squibb (United States)), Thomas Wegman(Bristol-Myers Squibb (United States))
Cited by 0
Related Papers
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis
|Annals of the Rheumatic Diseases|2012|1k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
The immune cell landscape in kidneys of patients with lupus nephritis
|Nature Immunology|2019|840